Contemporary management of the neurogenic bladder for multiple sclerosis patients

Urologic Clinics of North America

Volumn 37, Issue 4, 2010, Pages 547-557

  Stoffel, John T ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Multiple sclerosis; Neurogenic; Therapeutics; Urinary bladder

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATROPINE; BOTULINUM TOXIN; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DESMOPRESSIN; OXYBUTYNIN; PLACEBO; RESINIFERATOXIN; TAMSULOSIN;

BEHAVIOR THERAPY; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; HUMAN; INTERMITTENT CATHETERIZATION; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; NEUROGENIC BLADDER; NEUROMODULATION; NOCTURIA; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYMPTOM; URINARY DIVERSION; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; URODYNAMICS;

DECISION TREES; HUMANS; MULTIPLE SCLEROSIS; URINARY BLADDER; URINARY BLADDER, NEUROGENIC;

EID: 77957909120     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2010.06.003     Document Type: Review

References (114)

1. Noonan C.W., Kathman S.J., White M.C. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002, 58:136-138.
2. Detels R., Clark V.A., Valdiviezo N.L., et al. Factors associated with a rapid course of multiple sclerosis. Arch Neurol 1982, 39:337-341.
3. Phadke J.G. Clinical aspects of multiple sclerosis in North-East Scotland with particular reference to course and prognosis. Brain 1990, 113:1597-1628.
4. Noonan C.W., Williamson D.M., Henry J.P., et al. The prevalence of multiple sclerosis in 3 US communities. Prev Chronic Dis 2010, 7:A12.
5. Lauer K. Environmental risk factors in multiple sclerosis. Expert Rev Neurother 2010, 10:421-440.
6. Milo R., Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010, 9:A387-A394.
7. Hemminki K., Li X., Sundquist J., et al. Risk for multiple sclerosis in relatives and spouses of patients diagnosed with autoimmune and related conditions. Neurogenetics 2009, 10:5-11.
8. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50(1):121-127.
9. Gaspari M., Roveda G., Scandellari C., et al. An expert system for the evaluation of EDSS in multiple sclerosis. Artif Intell Med 2002, 25:187-210.
10. Koldewijn E.L., Hommes O.R., Lemmens A.J.G., et al. Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J Urol 1995, 154:169-173.
11. Siffrin V., Vogt J., Radbruch H., et al. Multiple sclerosis-candidate mechanisms underlying CNS atrophy. Trends Neurosci 2010, 33:202-210.
12. Brex P.A., Ciccarelli O., O'Riordan J.I., et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002, 346:158-164.
13. Charil A., Zijdenbos A.P., Taylor J., et al. Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: application to 452 patient data sets. Neuroimage 2003, 19:532-544.
14. Grasso M.G., Pozzilli C., Anzini A., et al. Relationship between bladder dysfunction and brain MRI in multiple sclerosis. Funct Neurol 1991, 6:289-292.
15. Pozzilli C., Grasso M.G., Bastianello S., et al. Structural brain correlates of neurologic abnormalities in multiple sclerosis. Eur Neurol 1992, 32:228-230.
16. Abou Zeid N.E., Weinshenker B.G., Keegan B.M. Gait apraxia in multiple sclerosis. Can J Neurol Sci 2009, 36:562-565.
17. Litwiller S.E., Frohman E.M., Zimmern P.E. Multiple sclerosis and the urologist. J Urol 1999, 161:743-757.
18. Tartaglino L.M., Friedman D.P., Flander A.E., et al. Multiple sclerosis and the spinal cord: MR appearance and correlation with clinical parameters. Radiology 1995, 195:725-732.
19. Oppenheimer D.R. The cervical cord in multiple sclerosis. Neuropathol Appl Neurobiol 1978, 4:151-162.
20. McGuire E.J., Savastano J.A. Urodynamic findings and long-term outcome management of patients with multiple sclerosis-induced lower urinary tract dysfunction. J Urol 1984, 132:713-715.
21. Kim Y.H., Goodman C., Omessi E., et al. The correlation of urodynamic findings with cranial magnetic resonance imaging findings in multiple sclerosis. J Urol 1998, 159:972-976.
22. Ukkonen M., Elovaara I., Dastidar P., et al. Urodynamic findings in primary progressive multiple sclerosis are associated with increased volumes of plaques and atrophy in the central nervous system. Acta Neurol Scand 2004, 109:100-105.
23. Araki I., Matsui M., Ozawa K., et al. Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol 2003, 169:1384-1387.
24. Ismael S.S., Epstein T., Bayle B., et al. Bladder cooling reflex in patients with multiple sclerosis. J Urol 2000, 164:1280-1284.
25. Hinson J.L., Boone T.B. Urodynamics and multiple sclerosis. Urol Clin North Am 1996, 23:475-481.
26. Kaplan S.A., Chancellor M.B., Blaivas J.G. Bladder and sphincter behavior in patients with spinal cord lesions. J Urol 1991, 146:113-117.
27. Dutta R., Trapp B.D. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007, 68:S22-S31. [discussion: S43-54].
28. Bartos A., Fialová L., Soukupová J., et al. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J Neurol 2007, 254:20-25.
29. Mahad D.J., Ziabreva I., Campbell G., et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009, 132:1161-1174.
30. Trapp B.D., Stys P.K. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009, 8:280-291.
31. de Groat W.C., Yoshimura N. Changes in afferent activity after spinal cord injury. Neurourol Urodyn 2010, 29:63-76.
32. Radziszewski P., Crayton R., Zaborski J., et al. Multiple sclerosis produces significant changes in urinary bladder innervation which are partially reflected in the lower urinary tract functional status-sensory nerve fibers role in detrusor overactivity. Mult Scler 2009, 15:860-868.
33. Wiseman O.J., Brady C.M., Hussain I.F., et al. The ultrastructure of bladder lamina propria nerves in healthy subjects and patients with detrusor hyperreflexia. J Urol 2002, 168:2040-2045.
34. Van Poppel H., Stessens R., Lazarides M., et al. Neuropathological examination of the alterations of the intrinsic innervation in multiple sclerosis cystopathy. Urol Int 1989, 44:321-326.
35. Mahajan S.T., Patel P.B., Marrie R.A. Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. J Urol 2010, 183:1432-1437.
36. McGrother C.W., Donaldson M.M., Hayward T., et al. Urinary storage symptoms and comorbidities: a prospective population cohort study in middle-aged and older women. Age Ageing 2006, 35:16-24.
37. Nakipoglu G.F., Kaya A.Z., Orhan G., et al. Urinary dysfunction in multiple sclerosis. J Clin Neurosci 2009, 16:1321-1324.
38. Khan F., Pallant J.F., Shea T.L., et al. Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort. Disabil Rehabil 2009, 31:1567-1576.
39. Betts C.D., D'Mellow M.T., Fowler C.J. Urinary symptoms and neurologic features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993, 56:245-250.
40. de Sèze M., Ruffion A., Denys P., et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007, 13:915-928.
41. Nortvedt M.W., Riise T., Frugård J., et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients 2 to 5 years after diagnosis. Mult Scler 2007, 13:106-112.
42. Blaivas J.G. Management of bladder dysfunction in multiple sclerosis. Neurology 1980, 30:12-18.
43. Sirls L.T., Zimmern P.E., Leach G.E. Role of limited evaluation and aggressive medical management in multiple sclerosis: a review of 113 patients. J Urol 1994, 151:946-950.
44. Onal B., Siva A., Buldu I., et al. Voiding dysfunction due to multiple sclerosis: a large scale retrospective analysis. Int Braz J Urol 2009, 35:326-333.
45. Schäfer W., Abrams P., Liao L., et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 2002, 21:261-274.
46. Dibenedetto M., Yalla S.V. Electrodiagnosis of striated urethral sphincter dysfunction. J Urol 1979, 122:361-365.
47. Koyanagi T., Takamatsu T., Taniguchi K. Further characterization of the external urethral sphincter in spinal cord injury: study during spinal shock and evolution of responsiveness to alpha-adrenergic stimulation. J Urol 1984, 131:1122-1126.
48. Lemack G.E., Frohman E.M., Zimmern P.E., et al. Urodynamic distinctions between idiopathic detrusor overactivity and detrusor overactivity secondary to multiple sclerosis. Urology 2006, 67:960-964.
49. Lemack G.E., Frohman E., Ramnarayan P. Women with voiding dysfunction secondary to bladder outlet dyssynergia in the setting of multiple sclerosis do not demonstrate significantly elevated intravesical pressures. Urology 2007, 69:893-897.
50. Ciancio S.J., Mutchnik S.E., Rivera V.M., et al. Urodynamic pattern changes in multiple sclerosis. Urology 2001, 57:239-245.
51. Blaivas J.G., Barbalias G.A. Detrusor-external sphincter dyssynergia in men with multiple sclerosis: an ominous urologic condition. J Urol 1984, 131:91-94.
52. Tauber S.C., Nau R., Gerber J. Systemic infections in multiple sclerosis and experimental autoimmune encephalomyelitis. Arch Physiol Biochem 2007, 113:124-130.
53. Hufschmidt A., Shabarin V., Rauer S., et al. Neurological symptoms accompanying urinary tract infections. Eur Neurol 2010, 63(3):180-183.
54. Metz L.M., McGuinness S.D., Harris C. Urinary tract infections may trigger relapse in multiple sclerosis. Axone 1998, 19:67-70.
55. Rapp N.S., Gilroy J., Lerner A.M. Role of bacterial infection in exacerbation of multiple sclerosis. Am J Phys Med Rehabil 1995, 74:415-418.
56. Urinary dysfunction and multiple sclerosis: evidence based management strategies for urinary dysfunction and multiple sclerosis. Multiple Sclerosis Council practice guidelines. Washington, DC: Paralyzed Veterans of America; 1999.
57. Porru D., Campus G., Garau A., et al. Urinary tract dysfunction in multiple sclerosis: is there a relation with disease-related parameters?. Spinal Cord 1997, 35:33-36.
58. Lemack G.E., Hawker K., Frohman E. Incidence of upper tract abnormalities in patients with neurovesical dysfunction secondary to multiple sclerosis: analysis of risk factors at initial urologic evaluation. Urology 2005, 65:854-857.
59. Krhut J., Hradílek P., Zapletalová O. Analysis of the upper urinary tract function in multiple sclerosis patients. Acta Neurol Scand 2008, 118:115-119.
60. Giannantoni A., Scivoletto G., Di Stasi S.M., et al. Urological dysfunctions and upper urinary tract involvement in multiple sclerosis patients. Neurourol Urodyn 1998, 17:89-98.
61. Bahmanyar S., Montgomery S.M., Hillert J., et al. Cancer risk among patients with multiple sclerosis and their parents. Neurology 2009, 72:1170-1177.
62. Rinaldi L., Perini P., Calabrese M., et al. Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks. Neurol Sci 2009, 30(Suppl 2):S171-S173.
63. Fowler C.J., Panicker J.N., Drake M., et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009, 80:470-477.
64. Nygaard I.E., Kreder K.J., Lepic M.M., et al. Efficacy of pelvic floor muscle exercises in women with stress, urge, and mixed urinary incontinence. Am J Obstet Gynecol 1996, 174(1 Pt 1):120-125.
65. De Ridder D., Ost D., Van der Aa F., et al. Conservative bladder management in advanced multiple sclerosis. Mult Scler 2005, 11:694-699.
66. De Ridder D., Vermeulen C., Ketelaer P., et al. Pelvic floor rehabilitation in multiple sclerosis. Acta Neurol Belg 1999, 99:61-64.
67. McClurg D., Ashe R.G., Marshall K., et al. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol Urodyn 2006, 25:337-348.
68. McClurg D., Ashe R.G., Lowe-Strong A.S. Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis-a double blind, placebo controlled, randomised clinical trial. Neurourol Urodyn 2008, 27:231-237.
69. Kalsi V., Fowler C.J. Therapy insight: bladder dysfunction associated with multiple sclerosis. Nat Clin Pract Urol 2005, 2:492-501.
70. Fader M., Glickman S., Haggar V., et al. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. J Urol 2007, 177:208-213.
71. Bennett N., O'Leary M., Patel A.S., et al. Can higher doses of oxybutynin improve efficacy in neurogenic bladder?. J Urol 2004, 171:749-751.
72. Nicholas R.S., Friede T., Hollis S., et al. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev 2009, 1. CD004193.
73. Freeman R.M., Adekanmi O., Waterfield M.R., et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006, 17:636-641.
74. O'Riordan J.I., Doherty C., Javed M., et al. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis?. J Urol 1995, 153:1114-1116.
75. EIu S., Borisov V.V., Demina T.L. Urologia 2004, 4:48-51. [in Russian].
76. Kilicarslan H., Ayan S., Vuruskan H., et al. Treatment of detrusor sphincter dyssynergia with baclofen and doxazosin. Int Urol Nephrol 2006, 38:537-541.
77. Valiquette G., Herbert J., Maede-D'Alisera P., et al. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996, 53:1270-1275.
78. Zahariou A., Karamouti M., Karagiannis G., et al. Maximal bladder capacity is a positive predictor of response to desmopressin treatment in patients with MS and nocturia. Int Urol Nephrol 2008, 40:65-69.
79. Bosma R., Wynia K., Havlíková E., et al. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand 2005, 112:1-5.
80. Vahter L., Zopp I., Kreegipuu M., et al. Clean intermittent self-catheterization in persons with multiple sclerosis: the influence of cognitive dysfunction. Mult Scler 2009, 15:379-384.
81. Fakas M., Souli M., Koratzanis G., et al. Effects of antimicrobial prophylaxis on asymptomatic bacteriuria and predictors of failure in patients with multiple sclerosis. J Chemother 2010, 22:36-43.
82. Stoffel J.T., McGuire E.J. Outcome of urethral closure in patients with neurologic impairment and complete urethral destruction. Neurourol Urodyn 2006, 25:19-22.
83. Meeks J.J., Erickson B.A., Helfand B.T., et al. Reconstruction of urethral erosion in men with a neurogenic bladder. BJU Int 2009, 103(3):378-381.
84. Wiart L., Joseph P.A., Petit H., et al. The effects of capsaicin on the neurogenic hyperreflexic detrusor. A double blind placebo controlled study in patients with spinal cord disease. Preliminary results. Spinal Cord 1998, 36:95-99.
85. de Sèze M., Wiart L., Joseph P.A., et al. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn 1998, 17:513-523.
86. Silva C., Silva J., Ribeiro M.J., et al. Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial. Eur Urol 2005, 48:650-655.
87. de Sèze M., Wiart L., de Sèze M.P., et al. Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study. J Urol 2004, 171(1):251-255.
88. MacDonald R., Monga M., Fink H.A., et al. Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects. J Spinal Cord Med 2008, 31:157-165.
89. Wefer B., Ehlken B., Bremer J., et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX(R)) therapy in Germany. World J Urol 2010, 28:385-390.
90. Ehren I., Volz D., Farrelly E., et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 2007, 41:335-340.
91. Gamé X., Mouracade P., Chartier-Kastler E., et al. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. J Pediatr Urol 2009, 5(3):156-164.
92. Kalsi V., Gonzales G., Popat R., et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007, 62:452-457.
93. Schurch B., Denys P., Kozma C.M., et al. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 2007, 52:850-858.
94. Schulte-Baukloh H., Schobert J., Stolze T., et al. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn 2006, 25:110-115.
95. Popat R., Apostolidis A., Kalsi V., et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005, 174:984-989.
96. Gallien P., Reymann J.M., Amarenco G., et al. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 2005, 76:1670-1676.
97. Smith C.P., Nishiguchi J., O'Leary M., et al. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 2005, 65:37-41.
98. Lekka E., Lee L.K. Successful treatment with intradetrusor botulinum-A toxin for urethral urinary leakage (catheter bypassing) in patients with end-staged multiple sclerosis and indwelling suprapubic catheters. Eur Urol 2006, 50:806-809. [discussion: 809-10].
99. Schulte-Baukloh H., Bigalke H., Miller K., et al. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol 2008, 15(5):407-415.
100. Marinkovic S.P., Gillen L.M. Sacral neuromodulation for multiple sclerosis patients with urinary retention and clean intermittent catheterization. Int Urogynecol J Pelvic Floor Dysfunct 2010, 21:223-228.
101. Wallace P.A., Lane F.L., Noblett K.L. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol 2007, 197(1):96. e1-5.
102. Chartier-Kastler E.J., Ruud Bosch J.L., Perrigot M., et al. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol 2000, 164:1476-1480.
103. Fjorback M.V., Rijkhoff N., Petersen T., et al. Event driven electrical stimulation of the dorsal penile/clitoral nerve for management of neurogenic detrusor overactivity in multiple sclerosis. Neurourol Urodyn 2006, 25(4):349-355.
104. Kabay S., Kabay S.C., Yucel M., et al. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn 2009, 28:964-968.
105. Fjorback M.V., van Rey F.S., van der Pal F., et al. Acute urodynamic effects of posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with MS. Eur Urol 2007, 51:464-470. [discussion: 471-2].
106. Fjorback M.V., Van Rey F.S., Rijkhoff N.J., et al. Electrical stimulation of sacral dermatomes in multiple sclerosis patients with neurogenic detrusor overactivity. Neurourol Urodyn 2007, 26:525-530.
107. Gamé X., Chartier-Kastler E., Ayoub N., et al. Outcome after treatment of detrusor-sphincter dyssynergia by temporary stent. Spinal Cord 2008, 46:74-77.
108. Stöhrer M., Kramer G., Goepel M., et al. Bladder autoaugmentation in adult patients with neurogenic voiding dysfunction. Spinal Cord 1997, 35(7):456-462.
109. Zachoval R., Pitha J., Medova E., et al. Augmentation cystoplasty in patients with multiple sclerosis. Urol Int 2003, 70:21-26.
110. Tan H.J., Stoffel J., Daignault S., et al. Ileovesicostomy for adults with neurogenic bladders: complications and potential risk factors for adverse outcomes. Neurourol Urodyn 2008, 27:238-243.
111. Hellenthal N.J., Short S.S., O'Connor R.C., et al. Incontinent ileovesicostomy: long term outcomes and complications. Neurourol Urodyn 2009, 28:483-486.
112. Gudziak M.R., Tiguert R., Puri K., et al. Management of neurogenic bladder dysfunction with incontinent ileovesicostomy. J Urol 1999, 54:1008-1011.
113. Vanni A.J., Cohen M.S., Stoffel J.T. Robotic-assisted ileovesicostomy: initial results. Urology 2009, 74(4):814-818.
114. Desmond A.D., Shuttleworth K.E. The results of urinary diversion in multiple sclerosis. Br J Urol 1977, 49:495-502.